A5032115602- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Neuroscience of respiration and sleep
- High Altitude and Hypoxia
- Heme Oxygenase-1 and Carbon Monoxide
- Sleep and Wakefulness Research
- Diabetes Management and Education
- Cardiovascular Function and Risk Factors
- Sphingolipid Metabolism and Signaling
- Iron Metabolism and Disorders
- Mobile Health and mHealth Applications
- Pancreatic and Hepatic Oncology Research
- Obstructive Sleep Apnea Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Dietary Effects on Health
- Gallbladder and Bile Duct Disorders
- Pregnancy and preeclampsia studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Gastrointestinal disorders and treatments
- Sulfur Compounds in Biology
- Medication Adherence and Compliance
- Mindfulness and Compassion Interventions
Medtronic (Switzerland)
2013-2025
Northwestern Medicine
2025
General Hospital of Drama
2025
Rosalind Franklin University of Medicine and Science
2025
Medtronic (Netherlands)
2015-2024
Instituto del Mar del Peru
1998-2022
Hospital General de México
2002-2020
Bakken Museum
2014-2018
Universidad de Valladolid
1997-2011
Centro de Investigación Biomédica en Red
2011
The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. preliminary performance of the in real-world settings was evaluated.
Abstract Aim To investigate real‐world glycaemic outcomes and goals achieved by users of the MiniMed 780G advanced hybrid closed loop (AHCL) system aged younger older than 15 years with type 1 diabetes (T1D). Materials Methods Data uploaded from 27 August 2020 to 22 July 2021 were aggregated retrospectively analysed based on self‐reported age (≤15 >15 years) for three cohorts: (a) post‐AHCL initiation, (b) 6‐month longitudinal initiation (c) pre‐ versus initiation. Analyses included mean...
Automated insulin delivery systems have improved glycaemic control in people with type 1 diabetes mellitus. The analysis investigated predictors of sensor glucose time-in-range (TIR; 70-180 mg/dl) based on real-world use the MiniMed 780G advanced hybrid closed-loop (AHCL) system.Data uploaded by system users from August 2020-July 2021 were analysed using univariate and multivariable models to identify baseline, demographic characteristics associated TIR after AHCL initiation (post-AHCL)....
We studied time in tight range (TITR) (70-140 mg/dL) real-world users of the MiniMed 780G system (MM780G).
The present report celebrates the benchmarking of 100,000 MiniMed™ 780G system users in Europe, Middle East, and Africa (EMEA) summarizes major insights into usability outcomes this system.
To investigate the impact of continuous glucose monitoring (CGM) on health-related quality life (HRQOL), treatment satisfaction (TS) medical resource use, and indirect costs in SWITCH study. was a multicentre, randomized, crossover Patients with type 1 diabetes (n = 153) using subcutaneous insulin infusion (CSII) were randomized to 12 month sensor-On/Off or sensor-Off/On sequence (6 months each treatment), 4-month washout between periods. HRQOL children TS adults measured validated...
Sensor-augmented pump (SAP) therapy can improve glycemic control, compared with multiple daily insulin injections or alone, without increasing the risk of hypoglycemia.
We studied real-world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), the effect each technology iteration MM on glycaemic control (technology analysis).CareLink data August 2020 to September 2022 were extracted. Endpoints included continuous glucose monitoring metrics. For geographical analysis, aggregated endpoints for MM780G calculated. user outcomes compared with when same individuals still using MM640G or MM670G system.On...
The concept of maintaining blood glucose levels within the 70-180 mg/dL range, known as time-in-range, has raised questions regarding its representation true physiological euglycemia. Some have speculated that focusing on time spent 70-140 introduced in tight range (TITR) through International Consensus statement, could serve a more precise metric for assessing normoglycemia individuals with type 1 diabetes. This article delves into current status TITR an emerging marker and explores how...
The mechanisms involved in hypoxic pulmonary vasoconstriction (HPV) are not yet fully defined. aim of the study was to determine role protein kinase C ζ (PKCζ) and neutral sphingomyelinase (nSMase) HPV. Ceramide content measured by immunocytochemistry voltage-gated potassium channel (KV) currents were recorded patch clamp technique isolated rat artery smooth muscle cells (PASMC). Contractile responses analysed arteries mounted a wire myograph. Pulmonary pressure anesthetized open-chest rats....
Aims To compare insulin pump therapy and multiple daily injections ( MDI ) in patients with type 2 diabetes receiving basal prandial analogues. Methods After a 2‐month dose‐optimization period, 331 glycated haemoglobin HbA1c levels ≥8.0% ≤12% were randomized to or continued for 6 months [randomization phase RP )]. The group was subsequently switched during 6‐month continuation CP ). primary endpoint the between‐group difference change mean from baseline end of . Results at 9% both groups. At...
To evaluate the real-world performance of MiniMed 670G system in Europe, individuals with diabetes.Data uploaded from October 2018 to July 2020 by living Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage time spent within (TIR), below (TBR) above (TAR) glycaemic ranges, use insulin consumed users 10 or more days sensor data after initial Auto Mode start determined. Another analysis based on suboptimally (GMI > 8.0%) well-controlled <...
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin required in significant portion people with T2D, despite recent developments antidiabetic medications. This study analyzes glycemic outcomes automated delivery (AID) users T2D different requirements. Methods: retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 April 2024). Four cohorts were identified based on phenotypes T2D: (A)...
To analyse blood glucose control according to continuous monitoring use in data from the CareLink database, and identify factors associated with continuation of sensor during sensor-augmented pump therapy.The analysis used 10 501 people Type 1 2 diabetes mellitus, whom 7916 (61.7%) had sensors for ≥ 15 days any 6-month period over a 2-year observation period. Data were analysed extent ( < 25%, 25-49%, 50-74% 75% time). Time discontinuation was also new users sensors.Compared patients lowest...
Cigarette smoke (CS) and chronic hypoxia (CH) can produce pulmonary hypertension. Similarities differences between both exposures their interaction have not been explored. The aim of the present study was to investigate effects CS CH, as single factors or in combination, on circulation guinea pig. 51 pigs were exposed for 12 weeks 32 sham-exposed. 50% animals each group additionally CH final 2 weeks. We measured artery pressure ( P pa ), weight ratio right ventricle (RV) left plus septum....
Abstract Aims To reassess the 6‐month efficacy and to assess 12‐month sustained of MiniMed™ 780G advanced hybrid closed‐loop automated insulin delivery (AID) system compared multiple daily injections plus intermittently scanned glucose monitoring (MDI+isCGM) in people with type 1 diabetes not meeting targets. Methods The ADAPT study was a prospective, multicentre, open‐label, randomized control trial diabetes, glycated haemoglobin (HbA1c) concentration at least 8.0% (64 mmol/mol), on...
Abstract Aim To report on the effectiveness and safety of MiniMed 780G automated insulin delivery system in real‐world users during month Ramadan. Materials Methods CareLink Personal data were extracted from Gulf region. Users included if they had ≥10 days sensor glucose Ramadan 2022 as well before after. For main analysis, continuous monitoring endpoints aggregated per reported by time day (daytime: 05.31‐18.00 h, night‐time). Additional analyses performed to study pace at which algorithm...
Abstract Aim Use of the MiniMed 780G system (MM780G) can result in a reduction mean and standard deviation (SD) sensor glucose (SG) values. We assessed significance coefficient variation (CV) as measure hypoglycaemia risk glycaemic control. Materials Methods Data from 10 404 MM780G users were analysed using multivariable logistic regression to assess contribution CV (a) risk, measured not reaching target <1% for time below range (TBR), (b) achieving targets time‐in‐range (TIR) >70%...
Obstructive sleep apnea is a frequent medical condition consisting in repetitive sleep-related episodes of upper airways obstruction and concurrent events arterial blood hypoxia. There association cardiovascular diseases other pathologies to this conforming the obstructive syndrome (OSAS). Laboratory models OSAS consist animals exposed intermittent hypoxia (IH) which also develop pathologies, mostly hypertension. The overall pathophysiology appears be linked hypoxia, would cause...
Background: The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. Research Design Methods: Patients glycated hemoglobin (HbA1c) levels ≥8% (64 mmol/mol) ≤12% (108 despite doses 0.7–1.8 U/kg/day via MDI were CSII (n=168) or continued (n=163). Changes evaluated using monitoring data collected over 6-day periods before 6 months after...